Quality of life in patients with minimal hepatic encephalopathy.

Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE

Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group
Original Publication: Beijing : WJG Press, c1998-

Quality of Life*; Hepatic Encephalopathy/*etiology ; Liver Cirrhosis/*complications; Anti-Bacterial Agents/therapeutic use ; Brain/physiopathology ; Electroencephalography ; Hepatic Encephalopathy/diagnosis ; Hepatic Encephalopathy/physiopathology ; Hepatic Encephalopathy/therapy ; Humans ; Liver Cirrhosis/diagnosis ; Neuropsychological Tests ; Probiotics/therapeutic use ; Severity of Illness Index ; Treatment Outcome

Minimal hepatic encephalopathy (MHE) represents the mildest type of hepatic encephalopathy (HE). This condition alters the performance of psychometric tests by impairing attention, working memory, psychomotor speed, and visuospatial ability, as well as electrophysiological and other functional brain measures. MHE is a frequent complication of liver disease, affecting up to 80% of tested patients, depending of the diagnostic tools used for the diagnosis. MHE is related to falls, to an impairment in fitness to drive and the development of overt HE, MHE severely affects the lives of patients and caregivers by altering their quality of life (QoL) and their socioeconomic status. MHE is detected in clinically asymptomatic patients through appropriate psychometric tests and neurophysiological methods which highlight neuropsychological alterations such as video-spatial orientation deficits, attention disorders, memory, reaction times, electroencephalogram slowing, prolongation of latency evoked cognitive potentials and reduction in the critical flicker frequency. Several treatments have been proposed for MHE treatment such as non-absorbable disaccharides, poorly absorbable antibiotics such rifaximin, probiotics and branched chain amino acids. However, because of the multiple diagnosis methods, the various endpoints of treatment trials and the variety of agents used in trials, to date the treatment of MHE is not routinely recommended apart from on a case-by-case basis. Aim of this review is analyze the burden of MHE on QoL of patients and provide a brief summary of therapeutic approaches.
Competing Interests: Conflict-of-interest statement: The authors have declared no conflicts of interest.

Cochrane Database Syst Rev. 2017 Feb 23;2:CD008716. (PMID: 28230908)
Hepatology. 2002 Jul;36(1):227-42. (PMID: 12085369)
Nutrients. 2018 Mar 09;10(3):. (PMID: 29522439)
Hepatology. 2007 Oct;46(4):1271-8. (PMID: 17886334)
Clin Gastroenterol Hepatol. 2012 Nov;10(11):1208-19. (PMID: 22728384)
Metab Brain Dis. 2013 Jun;28(2):301-5. (PMID: 23463488)
Am J Gastroenterol. 1997 Jan;92(1):66-72. (PMID: 8995940)
Liver Transpl. 2000 Nov;6(6):779-83. (PMID: 11084068)
Arch Neurol. 1996 Aug;53(8):758-63. (PMID: 8759982)
Hepatology. 2007 Apr;45(4):879-85. (PMID: 17393525)
J Clin Gastroenterol. 2019 Mar;53(3):226-230. (PMID: 29668561)
Hepatology. 2007 Mar;45(3):833-4. (PMID: 17326210)
Metab Brain Dis. 2004 Dec;19(3-4):253-67. (PMID: 15554421)
Med Care. 1981 Aug;19(8):787-805. (PMID: 7278416)
Gut. 2004 May;53(5):744-9. (PMID: 15082595)
Expert Rev Gastroenterol Hepatol. 2008 Dec;2(6):785-90. (PMID: 19090738)
J Clin Epidemiol. 1998 Nov;51(11):1025-36. (PMID: 9817120)
Am J Gastroenterol. 2000 Aug;95(8):2029-34. (PMID: 10950053)
J Gastroenterol Hepatol. 2001 Mar;16(3):322-7. (PMID: 11339425)
Metab Brain Dis. 2005 Dec;20(4):381-92. (PMID: 16382348)
Dig Dis Sci. 2003 Aug;48(8):1622-6. (PMID: 12924658)
JAMA Intern Med. 2014 Nov;174(11):1727-33. (PMID: 25243839)
Gut. 1999 Aug;45(2):295-300. (PMID: 10403745)
J Hepatol. 1986;3(1):75-82. (PMID: 3745889)
J Hepatol. 1999 May;30(5):890-5. (PMID: 10365817)
Hepatology. 1999 Jun;29(6):1662-7. (PMID: 10347105)
Gastroenterology. 2011 Feb;140(2):478-487.e1. (PMID: 20849805)
J Clin Sleep Med. 2008 Feb 15;4(1):45-9. (PMID: 18350962)
Hepatology. 2014 Aug;60(2):715-35. (PMID: 25042402)
Saudi J Gastroenterol. 2014 Jul-Aug;20(4):225-32. (PMID: 25038208)
Clin Gastroenterol Hepatol. 2008 Oct;6(10):1135-9; quiz 1065. (PMID: 18928938)
Pol J Radiol. 2018 May 15;83:e215-e219. (PMID: 30627238)
Am J Gastroenterol. 2011 Mar;106(3):476-82. (PMID: 20978484)
Metab Brain Dis. 2001 Jun;16(1-2):37-41. (PMID: 11726087)
Eur J Gastroenterol Hepatol. 2008 Jun;20(6):506-11. (PMID: 18467909)
Eur J Gastroenterol Hepatol. 2011 Aug;23(8):725-32. (PMID: 21646910)
Int J Clin Exp Med. 2015 Feb 15;8(2):2954-7. (PMID: 25932262)
Hepatology. 2007 Mar;45(3):549-59. (PMID: 17326150)
Neurol Sci. 2008 Sep;29(4):237-40. (PMID: 18810597)
J Hepatol. 2005 Apr;42(4):573-7. (PMID: 15763344)
Hepatology. 2012 Jan;55(1):184-91. (PMID: 21858847)
Gut. 1990 Jan;31(1):82-7. (PMID: 2318434)
Am J Gastroenterol. 2011 Feb;106(2):307-16. (PMID: 21157444)
Acta Orthop. 2008 Apr;79(2):269-80. (PMID: 18484255)
Hepatology. 2008 Feb;47(2):596-604. (PMID: 18000989)
J Hepatol. 2000 May;32(5):859-61. (PMID: 10845675)
Trials. 2016 Feb 29;17(1):111. (PMID: 26926775)
Aliment Pharmacol Ther. 2011 Oct;34(8):853-61. (PMID: 21848797)
Am J Gastroenterol. 2011 Sep;106(9):1646-53. (PMID: 21556040)
Clin Gastroenterol Hepatol. 2013 Nov;11(11):1511-6. (PMID: 23707462)
Am J Gastroenterol. 2007 Apr;102(4):754-60. (PMID: 17222319)
Am J Gastroenterol. 2001 Jul;96(7):2199-205. (PMID: 11467653)
J Hepatol. 2000 May;32(5):748-53. (PMID: 10845661)
Liver Int. 2017 Jul;37(7):1013-1022. (PMID: 27988985)
J Hepatol. 2007 Jul;47(1):67-73. (PMID: 17459511)
Arch Gen Psychiatry. 2004 Feb;61(2):119-29. (PMID: 14757588)
Metab Brain Dis. 2017 Apr;32(2):595-605. (PMID: 28070704)
J Hepatol. 2001 May;34(5):768-73. (PMID: 11434627)
Am J Gastroenterol. 2008 Jul;103(7):1707-15. (PMID: 18691193)
Eur J Gastroenterol Hepatol. 2011 Nov;23(12):1250-7. (PMID: 21971378)
J Clin Exp Hepatol. 2019 Jan-Feb;9(1):137-145. (PMID: 30765947)
Clin Gastroenterol Hepatol. 2014 Jun;12(6):1003-8.e1. (PMID: 24246768)
N Engl J Med. 1981 Oct 22;305(17):982-7. (PMID: 7278922)
Gastroenterology. 2001 Jan;120(1):170-8. (PMID: 11208726)
Ann Gastroenterol. 2018 Mar-Apr;31(2):151-164. (PMID: 29507462)
Hepatology. 2012 Jun;55(6):1922-30. (PMID: 22213000)
Aliment Pharmacol Ther. 2018 Aug;48(3):313-321. (PMID: 29863286)
Pharmacoeconomics. 2010;28(5):395-409. (PMID: 20402541)
Dig Dis Sci. 2007 Nov;52(11):3259-65. (PMID: 17393330)
Scand J Gastroenterol. 2011 Jun;46(6):750-9. (PMID: 21443422)
Aliment Pharmacol Ther. 2014 May;39(10):1113-25. (PMID: 24628464)
Liver Int. 2016 Mar;36(3):378-85. (PMID: 26201713)
Neuroradiology. 2014 Oct;56(10):885-91. (PMID: 25060166)
J Arthroplasty. 2005 Jun;20(4):460-6. (PMID: 16124961)
Hepatology. 1998 Jul;28(1):45-9. (PMID: 9657095)
Trop Gastroenterol. 2011 Apr-Jun;32(2):128-32. (PMID: 21922877)
Hepatol Res. 2014 Oct;44(10):E92-9. (PMID: 24033755)
Hepatology. 1998 Feb;27(2):339-45. (PMID: 9462628)
World J Gastroenterol. 2007 Jun 7;13(21):3003-8. (PMID: 17589955)
Hepatology. 2002 Mar;35(3):716-21. (PMID: 11870389)
Cochrane Database Syst Rev. 2016 May 06;(5):CD003044. (PMID: 27153247)
Methods Find Exp Clin Pharmacol. 2002;24 Suppl D:119-22. (PMID: 12575478)
Liver Transpl. 2005 Feb;11(2):218-23. (PMID: 15666392)

Keywords: Cirrhosis; Covert hepatic encephalopathy; Health related quality of life; Minimal hepatic encephalopathy

0 (Anti-Bacterial Agents)

Date Created: 20190110 Date Completed: 20190128 Latest Revision: 20231005

20240628

PMC6319138

10.3748/wjg.v24.i48.5446

30622374